• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺微小乳头状癌与尸检中的隐匿性甲状腺乳头状癌不同。

Papillary thyroid microcarcinomas are different from latent papillary thyroid carcinomas at autopsy.

机构信息

Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Biomedical Research Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

出版信息

J Korean Med Sci. 2014 May;29(5):676-9. doi: 10.3346/jkms.2014.29.5.676. Epub 2014 Apr 25.

DOI:10.3346/jkms.2014.29.5.676
PMID:24851024
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4024958/
Abstract

The aim of this study was to review the literature of latent papillary thyroid carcinomas (PTCs) discovered at autopsy and describe the available pathologic and demographic differences from a group of papillary thyroid microcarcinomas (PTMCs) the reported in a previous publication. We searched the PubMed for published articles describing latent thyroid carcinomas detected at autopsy. Meta-analysis was performed to identify differences between the clinicopathologic features of PTMCs analyzed previously in our institution (Group I) and those of latent PTCs described in autopsy studies (Group II). We identified 1,355 patients with PTMC (Group I) and 989 with latent PTCs (Group II). Mean patient age was 47.3 yr in Group I and 64.5 yr in Group II. The male:female ratio was 1:10.9 in Group I and 1:1 in Group II. Most PTMCs (67.6%) were larger than 0.5 cm in size, whereas most latent PTCs were <1-3 mm in diameter. The rates of multifocality were 24.7% in Group I and 30.5% in Group II, and the rates of cervical lymph node metastasis were 33.4% in Group I and 10.0% in Group II. Currently available data indicated that clinically evident PTMCs differ from latent PTCs detected at autopsy. Therefore, these two entities should be regarded as different.

摘要

本研究旨在回顾尸检中发现的隐匿性甲状腺乳头状癌(PTC)的文献,并描述与先前发表的一组甲状腺微小乳头状癌(PTMC)相比,尸检中发现的隐匿性 PTC 的可用病理和人口统计学差异。我们在 PubMed 上搜索描述尸检中发现的隐匿性甲状腺癌的已发表文章。进行荟萃分析以确定之前在我们机构分析的 PTMC(I 组)的临床病理特征与尸检研究中描述的隐匿性 PTC(II 组)之间的差异。我们确定了 1355 例 PTMC(I 组)和 989 例隐匿性 PTC(II 组)患者。I 组患者的平均年龄为 47.3 岁,II 组为 64.5 岁。I 组男女比例为 1:10.9,II 组为 1:1。大多数 PTMC(67.6%)大于 0.5cm,而大多数隐匿性 PTC 直径小于 1-3mm。I 组的多灶性发生率为 24.7%,II 组为 30.5%,I 组的颈部淋巴结转移率为 33.4%,II 组为 10.0%。目前可用的数据表明,临床上明显的 PTMC 与尸检中发现的隐匿性 PTC 不同。因此,这两种实体应被视为不同的疾病。

相似文献

1
Papillary thyroid microcarcinomas are different from latent papillary thyroid carcinomas at autopsy.甲状腺微小乳头状癌与尸检中的隐匿性甲状腺乳头状癌不同。
J Korean Med Sci. 2014 May;29(5):676-9. doi: 10.3346/jkms.2014.29.5.676. Epub 2014 Apr 25.
2
Utility of high b-value (2000 sec/mm2) DWI with RESOLVE in differentiating papillary thyroid carcinomas and papillary thyroid microcarcinomas from benign thyroid nodules.高 b 值(2000 sec/mm 2 )弥散加权成像联合 RESOLVE 技术鉴别甲状腺乳头状癌及微小癌与甲状腺良性结节的价值。
PLoS One. 2018 Jul 18;13(7):e0200270. doi: 10.1371/journal.pone.0200270. eCollection 2018.
3
Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3607 patients at a single institution.甲状腺微小乳头状癌淋巴结转移及生存率的临床预测因素:单中心3607例患者分析
J Surg Res. 2018 Jan;221:128-134. doi: 10.1016/j.jss.2017.08.007. Epub 2017 Sep 19.
4
Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples.利用超声引导下细针穿刺活检样本的蛋白质组学分析破译甲状腺乳头状微癌淋巴结转移的新型生物标志物。
J Proteomics. 2019 Jul 30;204:103414. doi: 10.1016/j.jprot.2019.103414. Epub 2019 Jun 10.
5
Using Ultrasonography to Evaluate the Relationship between Capsular Invasion or Extracapsular Extension and Lymph Node Metastasis in Papillary Thyroid Carcinomas.利用超声检查评估甲状腺乳头状癌的包膜侵犯或包膜外扩展与淋巴结转移之间的关系。
Chin Med J (Engl). 2017 Jun 5;130(11):1309-1313. doi: 10.4103/0366-6999.206339.
6
Clinicopathological features of papillary thyroid microcarcinoma with a diameter less than or equal to 5 mm.直径小于或等于 5mm 的甲状腺微小乳头状癌的临床病理特征。
Am J Otolaryngol. 2019 Jul-Aug;40(4):560-563. doi: 10.1016/j.amjoto.2019.05.003. Epub 2019 May 8.
7
Extent of lateral neck dissection for papillary thyroid microcarcinomas.甲状腺微小乳头状癌颈侧区清扫的范围。
Head Neck. 2019 May;41(5):1367-1371. doi: 10.1002/hed.25570. Epub 2018 Dec 10.
8
Total surface area is useful for differentiating between aggressive and favorable multifocal papillary thyroid carcinomas.总表面积有助于鉴别侵袭性和预后良好的多灶性乳头状甲状腺癌。
Yonsei Med J. 2015 Mar;56(2):355-61. doi: 10.3349/ymj.2015.56.2.355.
9
Clinical features and therapeutic outcomes of patients with papillary thyroid microcarcinomas and larger tumors.甲状腺微小乳头状癌和较大肿瘤患者的临床特征及治疗结果
Nucl Med Commun. 2019 May;40(5):477-483. doi: 10.1097/MNM.0000000000000991.
10
SHOULD MULTIFOCAL PAPILLARY THYROID CARCINOMAS CLASSIFIED AS T1A WITH A TUMOR DIAMETER SUM OF 1 TO 2 CENTIMETERS BE RECLASSIFIED AS T1B?肿瘤直径总和为1至2厘米的多灶性乳头状甲状腺癌应重新分类为T1b吗? 应将其归类为T1a吗?
Endocr Pract. 2017 May;23(5):526-535. doi: 10.4158/EP161488.OR. Epub 2017 Feb 3.

引用本文的文献

1
Thirty years of active surveillance for low-risk thyroid cancer, lessons learned and future directions.30 年低危甲状腺癌主动监测经验,教训与未来方向。
Rev Endocr Metab Disord. 2024 Feb;25(1):65-78. doi: 10.1007/s11154-023-09844-y. Epub 2023 Oct 14.
2
Trends in incidence and overdiagnosis of thyroid cancer in China, Japan, and South Korea.中国、日本和韩国甲状腺癌发病及过度诊断趋势
Cancer Sci. 2023 Oct;114(10):4052-4062. doi: 10.1111/cas.15909. Epub 2023 Jul 24.
3
Papillary thyroid carcinoma within a mature cystic ovarian teratoma.卵巢成熟囊性畸胎瘤内的甲状腺乳头状癌。
Wien Med Wochenschr. 2023 Jun;173(9-10):245-247. doi: 10.1007/s10354-023-01016-6. Epub 2023 May 11.
4
Conservative management of low-risk papillary thyroid carcinoma: a review of the active surveillance experience.低风险甲状腺乳头状癌的保守治疗:主动监测经验综述
Thyroid Res. 2023 Mar 13;16(1):6. doi: 10.1186/s13044-023-00148-6.
5
The 2017 United States Preventive Services Task Force Recommendation for Thyroid Cancer Screening Is No Longer the Gold Standard.2017年美国预防服务工作组关于甲状腺癌筛查的建议不再是金标准。
Endocrinol Metab (Seoul). 2023 Feb;38(1):72-74. doi: 10.3803/EnM.2023.106. Epub 2023 Feb 27.
6
Active surveillance of highly suspicious thyroid nodules cohort in China shows a worse psychological status in younger patients.中国对高度可疑甲状腺结节队列的主动监测显示,年轻患者的心理状态较差。
Front Oncol. 2022 Aug 26;12:981495. doi: 10.3389/fonc.2022.981495. eCollection 2022.
7
Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center.风险分层的甲状腺微小乳头状癌:单中心的术后管理和治疗结果。
Endocrine. 2022 Jun;77(1):134-142. doi: 10.1007/s12020-022-03060-5. Epub 2022 Apr 27.
8
The Application Value of the Central Lymph Node Metastasis Risk Assessment Model in Papillary Thyroid Microcarcinoma of Stage cN0: A Study of 828 Patients.中央淋巴结转移风险评估模型在 cN0 期甲状腺微小乳头状癌中的应用价值:一项 828 例患者的研究。
Front Endocrinol (Lausanne). 2022 Mar 10;13:843573. doi: 10.3389/fendo.2022.843573. eCollection 2022.
9
Cytomorphological study of thyroid carcinoma.甲状腺癌的细胞形态学研究
Exp Ther Med. 2022 Feb;23(2):117. doi: 10.3892/etm.2021.11040. Epub 2021 Dec 6.
10
The Overdiagnosis of Thyroid Micropapillary Carcinoma: The Rising Incidence, Inert Biological Behavior, and Countermeasures.甲状腺微小乳头状癌的过度诊断:发病率上升、惰性生物学行为及应对措施
J Oncol. 2021 Jul 9;2021:5544232. doi: 10.1155/2021/5544232. eCollection 2021.

本文引用的文献

1
Managing thyroid microcarcinomas.甲状腺微小癌的管理。
Yonsei Med J. 2012 Jan;53(1):1-14. doi: 10.3349/ymj.2012.53.1.1.
2
The role of initiating and promoting factors in the pathogenesis of tumors of the thyroid.启动和促进因素在甲状腺肿瘤发病机制中的作用。
Br J Cancer. 1948 Sep;2(3):273-80. doi: 10.1038/bjc.1948.32.
3
Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake.在不同碘摄入量地区进行的尸检系列中发现的甲状腺微小癌的流行病学。
Thyroid. 2005 Feb;15(2):152-7. doi: 10.1089/thy.2005.15.152.
4
Latent carcinoma of the thyroid in Austria: a systematic autopsy study.奥地利甲状腺潜伏癌:一项系统性尸检研究
Endocr Pathol. 2001 Spring;12(1):23-31. doi: 10.1385/ep:12:1:23.
5
Papillary microcarcinoma of the thyroid gland.甲状腺微小乳头状癌
Br J Surg. 1996 Dec;83(12):1674-83. doi: 10.1002/bjs.1800831206.
6
Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods.
Cancer. 1993 Jun 15;71(12):4022-9. doi: 10.1002/1097-0142(19930615)71:12<4022::aid-cncr2820711236>3.0.co;2-o.
7
Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients.白俄罗斯明斯克地区的隐匿性甲状腺癌。对215例患者的尸检研究。
Histopathology. 1993 Oct;23(4):319-25. doi: 10.1111/j.1365-2559.1993.tb01214.x.
8
Thyroid carcinomas in Singapore autopsies.
Pathology. 1994 Jan;26(1):20-2. doi: 10.1080/00313029400169031.
9
Occult thyroid carcinoma at autopsy in Malmö, Sweden.
Cancer. 1981 Jan 15;47(2):319-23. doi: 10.1002/1097-0142(19810115)47:2<319::aid-cncr2820470218>3.0.co;2-a.
10
Occult carcinoma of the thyroid gland.
Pathol Res Pract. 1984 Sep;179(1):88-91. doi: 10.1016/S0344-0338(84)80066-7.